New drug duo takes on stubborn Epstein-Barr virus
NCT ID NCT07369739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs, golidocitinib and selinexor, can control chronic active Epstein-Barr virus disease (CAEBVD). Researchers will enroll 28 adults with CAEBVD and track how well the treatment reduces symptoms and lowers virus levels in the blood. It is an early-phase trial without a placebo group, so results will show if the approach is promising enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
golidocitinib and selinexor (combination drug therapy)
What this could lead to
If it works, this could offer a new treatment option to control chronic active Epstein-Barr virus disease and reduce virus levels in the blood.
What could go wrong
This is an early-phase trial with only 28 participants and no comparison group, so results may not apply broadly. The drugs may cause side effects or fail to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••